Nuvation Bio, a global oncology company dedicated to addressing some of the most challenging areas in cancer care, has announced that the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) has accepted for review a Marketing Authorisation Application (MAA) submitted by its partner, Eisai Co., Ltd., for taletrectinib as a treatment for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC).

The submission was made under the International Recognition Procedure, a pathway designed to accelerate patient access to medicines by considering approvals from trusted international regulatory authorities. The MHRA will now conduct its assessment to determine whether the therapy should be authorized in the United Kingdom.

In January 2026, Nuvation Bio and Eisai entered into an exclusive licensing and collaboration agreement covering Europe and several territories outside the United States, China, and Japan, with the goal of expanding global access to taletrectinib. The oral therapy, marketed as IBTROZI® in the U.S. and Japan, is intended for patients with advanced ROS1+ NSCLC. The European Medicines Agency accepted the drug's MAA for review in March 2026, and additional regulatory submissions are planned in Canada and other regions included within Eisai's licensed territories.

Approximately 50,200 new lung cancer cases are diagnosed annually in the United Kingdom. Non-small cell lung cancer accounts for roughly 80% to 85% of these cases, with an estimated 2% of patients carrying the ROS1-positive mutation.

The regulatory filing is supported by findings from the pivotal Phase 2 TRUST-I and TRUST-II clinical trials, which evaluated taletrectinib in patients worldwide. Combined analyses from the TRUST program were first published in the Journal of Clinical Oncology in April 2025. Updated data, reflecting extended patient follow-up, were presented at the American Association for Cancer Research (AACR) Annual Meeting in April 2026, further strengthening the treatment's observed efficacy and safety profile. Additional findings from the TRUST-I study were also published in the Journal of Clinical Oncology during the same month.

David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio, welcomed the advancement of taletrectinib into the U.K. regulatory review process following recent progress in Europe. He noted that the therapy has already demonstrated meaningful benefits for patients in the United States, China, and Japan, and emphasized that the latest milestone represents another important step toward broadening global access to the treatment.

In June 2025, the U.S. Food and Drug Administration granted full approval to taletrectinib for patients with locally advanced or metastatic ROS1+ NSCLC across multiple lines of therapy, following a Priority Review process and the awarding of two Breakthrough Therapy designations. The treatment has also been approved in Japan, where it is marketed by Nippon Kayaku, and in China, where Innovent Biologics markets it under the brand name DOVBLERON.

Eisai's licensed territories for taletrectinib include Europe, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, Vietnam, and India.

Hyundai Bioscience has revealed an ambitious new plan aimed at addressing worldwide viral outbreaks, confirming the launch of its Phase 2 clinical trials in the United States.

During its presentation at Biotech Showcase 2026, the company outlined a forward-looking antiviral approach centered on Xafty, a broad-spectrum therapeutic designed to combat multiple viruses. Marking a decisive shift in focus, the company stated that preparations in Vietnam have been finalized and that efforts are now moving to the U.S. market.

A Long-Awaited Broad-Spectrum Antiviral
A major focus of the announcement was the clinical framework developed in partnership with Dr. Davey Smith, Professor of Medicine and Assistant Vice Chancellor at the University of California, San Diego (UCSD).

Dr. Smith, an internationally recognized infectious disease specialist who previously headed the U.S. government’s ACTIV-2 COVID-19 clinical trials, described the current public health landscape in the U.S. as a “tripledemic” driven by influenza, RSV, and emerging COVID-19 strains—conditions that currently lack a single, comprehensive treatment solution.

Commenting on the trial design, Dr. Smith explained that Xafty offers the potential to address several viral infections simultaneously. He noted that the innovative “basket trial” model enables efficient evaluation across multiple viruses and represents a practical response to the ongoing multi-virus challenge. Emphasizing urgency, he stressed the importance of accelerating clinical progress to bring new treatment options to patients as quickly as possible.

“One Drug, Two Tracks”: A Global Strategy
Hyundai Bioscience also introduced its “One Drug, Two Tracks” development model, which deploys Xafty across two distinct clinical pathways:

By advancing the same drug in different viral settings, the company aims to demonstrate Xafty’s wide-ranging antiviral capability, spanning both mosquito-transmitted and respiratory infections. The strategy mirrors the versatility of modern antibiotics that are effective against multiple bacterial strains.

Jason Kim, CEO of Hyundai Bioscience USA, noted that discussions at the showcase confirmed strong alignment between the company’s clinical strategy and unmet needs within the U.S. healthcare system. He added that all preparations are in place and that the company is ready to promptly file its Investigational New Drug (IND) application with the U.S. Food and Drug Administration.

Looking Ahead: A New Era in Antiviral Treatment
The presentation concluded with a forward-looking vision for global health. Dr. Smith observed that antiviral development has historically been reactive, focused on chasing evolving variants. He expressed confidence that a preventive, broad-spectrum approach could redefine the field, positioning this clinical trial as a potential milestone in the development of antivirals capable of targeting multiple viruses with a single therapy.